Shanghai, China, August 29, 2025 – Fosun Pharma (600196.SH; 02196.HK) and Accro Bioscience (Accro) today announced that Accro will grant exclusive rights to develop, manufacture, and commercialize its independently developed, highly selective TYK2/JAK1 inhibitor to Fosun Pharma in Greater China (including Chinese Mainland, Hong Kong SAR, and Macau SAR). Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR).

On the morning of 29 August, Fosun International held an interim results presentation in Shanghai, with attendees including Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu, Co-CEO of Fosun International, Xu Xiaoliang, Co-CEO of Fosun International, Gong Ping, CFO of Fosun International, along with numerous institutional investors and analysts.

(August 27, 2025, Shanghai, China）— Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has entered into a License Agreement with Sitala, a UK-based biotech company focused on developing innovative drugs for inflammation and autoimmune diseases. Under the agreement, Fosun Pharma Industrial will grant Sitala exclusive rights to develop, manufacture, and commercialize the small molecule inhibitor FXS6837 and products containing this active ingredient globally (except Chinese Mainland, Hong Kong SAR and Macau SAR). The licensed field includes the diagnosis and treatment of human and animal diseases. Fosun Pharma will retain the rights to develop, manufacture, and commercialize FXS6837 in Chinese Mainland, Hong Kong SAR and Macau SAR.

(Shanghai, August 27, 2025) — Fosun International Limited (00656.HK) today announced the interim results of its subsidiary, Fosun Tourism Group (the “Group”), for the six months ended June 30, 2025. During the reporting period, Fosun Tourism Group delivered steady growth, with revenue reaching a historical high and adjusted net profit increasing by over 40% year-on-year.

(Hong Kong, Shanghai, 27 August 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”).

(August 26, 2025, Shanghai, China) — On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 (“the Reporting Period”).

Shanghai, China, August 25, 2025 – Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow.

Shanghai, China, August 22, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject has been dosed in the US for HLX43-NSCLC201, a phase 2 international muticenter clinical trial of HLX43, its innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Henlius is vigorously advancing the global development of HLX43, with an international multi-region phase 2 clinical trial initiated in China, the US, Australia, and Japan. At present, no PD-L1 targeting ADC has been approved for marketing globally.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed anti-PD-1 monoclonal antibody (mAb) serplulimab was recently prescribed for the first time in both Europe and India. This milestone marks that this Chinese innovative biologic is now in clinical use in Europe as well as the world’s most populous country, further accelerating the global accessibility of innovative biologics.